<DOC>
	<DOCNO>NCT00020774</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy use different way stop tumor cell divide stop grow die . Combining one drug may kill tumor cell . PURPOSE : Randomized phase II trial compare effectiveness SCH 66336 without gemcitabine follow surgery surgery alone treat patient primary liver cancer .</brief_summary>
	<brief_title>SCH 66336 With Without Gemcitabine Followed Surgery Compared With Surgery Alone Treating Patients With Primary Liver Cancer</brief_title>
	<detailed_description>OBJECTIVES : I . Determine biologic activity toxicity neoadjuvant SCH 66336 without gemcitabine follow surgical resection v surgical resection alone patient resectable primary liver cancer . OUTLINE : This randomize , open-label study . Patients randomize one three treatment arm . Arm I : Patients receive neoadjuvant oral SCH 66336 twice daily 14 day follow surgical resection . Arm II : Patients receive neoadjuvant oral SCH 66336 twice daily 14 day gemcitabine IV 30 minute weekly 2 week follow surgical resection . Arm III : Patients undergo surgical resection . Patients receive neoadjuvant therapy prior resection . PROJECTED ACCRUAL : Approximately 30 patient ( 10 per treatment arm ) accrue study .</detailed_description>
	<mesh_term>Liver Neoplasms</mesh_term>
	<mesh_term>Gemcitabine</mesh_term>
	<criteria>Histologically cytologically confirm resectable primary hepatocellular carcinoma cholangiocarcinoma 18 Karnofsky 70100 % Hematopoietic : Absolute neutrophil count great 1,500/mm3 Platelet count least 100,000/mm3 Hemoglobin least 9 g/dL Hepatic : Bilirubin great 2 time upper limit normal ( ULN ) SGOT SGPT great 5 time ULN Albumin least 2.5 g/dL INR le 1.3 Renal : Creatinine great 1.5 mg/dL Cardiovascular : QTc prolongation great 440 msec Other : Negative pregnancy test Fertile patient must use effective barrier contraception At least 6 week since prior radiotherapy recover At least 6 week since prior surgery recover At least 6 week since prior systemic therapy recover metastatic disease outside liver pregnant nursing malabsorption gastrointestinal ( GI ) condition would preclude ability take oral medication and/or GI absorption ( e.g. , partial small bowel obstruction ) nonmalignant systemic disease would preclude study active uncontrolled infection No grade II nausea grade I vomit despite antiemetic medication concurrent immunotherapy Chemotherapy : No concurrent chemotherapy concurrent hormonal therapy include estrogen therapy concurrent oral contraceptive hormonal method Concurrent megestrol acetate allow concurrent corticosteroid ( except nausea/vomiting gemcitabine administration ) concurrent CYP3A4 inhibitor inducer include : Azoles ( e.g. , itraconazole , clotrimazole , fluconazole , ketoconazole ) Macrolide antibiotic ( e.g. , azithromycin , clarithromycin , erythromycin ) Cyclosporine Grapefruit Antiepileptic medication ( e.g. , phenytoin , carbamazepine , phenobarbital ) Antibiotics tuberculosis ( e.g. , rifampin isoniazid ) concurrent HIV protease inhibitor ( e.g. , amprenavir , ritonavir , saquinavir mesylate ) concurrent cisapride concurrent investigational therapy</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2012</verification_date>
	<keyword>localize resectable adult primary liver cancer</keyword>
	<keyword>recurrent adult primary liver cancer</keyword>
	<keyword>adult primary hepatocellular carcinoma</keyword>
	<keyword>adult primary cholangiocellular carcinoma</keyword>
</DOC>